Foghorn Therapeutics Inc. Long-Term Debt, Maturity, Remainder of Fiscal Year
Foghorn Therapeutics Inc. (FHTX) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $0 as of 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2021-11-09
- 2021-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2021-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2021-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2020-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $1.50M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2021-09-30 | $0.00 10-Q · filed 2021-11-09 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-10 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-11 |
| 2020-09-30 | $1.50M 10-Q · filed 2020-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |